NCT05606055View on ClinicalTrials.gov

The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

March 3, 2022

Conditions
HIV-1-infection
Interventions
DRUG

BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato

This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.

Trial Locations (1)

Unknown

Hospital FUNDACIÓN JIMÉNEZ DÍAZ, Madrid

All Listed Sponsors
lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT05606055 - The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection | Biotech Hunter | Biotech Hunter